Proteasome

Proteasome-IN-5 is a selective proteasome inhibitor that disrupts the ubiquitin-proteasome pathway, leading to the accumulation of polyubiquitinated proteins. This compound exhibits significant antitumor activity and is valuable in research related to cancer biology and neurodegenerative diseases. Proteasome-IN-5 can be utilized to study the role of proteasomal degradation in cellular processes and to explore potential therapeutic strategies targeting proteasome dysfunction.

LU-001i is a selective inhibitor of the proteasome β1i subunit (LMP2). While LU-001i exhibits minimal immunomodulatory effects as a standalone treatment, its combination with LMP7 inhibitors, such as PRN1126, enhances anti-inflammatory and immunomodulatory activities. This reagent is valuable for investigating the mechanisms underlying autoimmune diseases and developing targeted therapeutic strategies.

A-933548 is a highly potent and selective inhibitor of calpain, demonstrating a Ki value of 18 nM. This compound's ability to modulate calpain activity makes it a valuable tool for research into neurodegenerative disorders, particularly Alzheimer's disease. Its specificity for calpain allows for detailed studies of calpain-mediated pathways and potential therapeutic interventions.

Z-Gly-Pro-Phe-Leu-CHO is a tetrapeptide aldehyde that serves as a highly selective and potent inhibitor of the proteasome. It demonstrates significant inhibition with Ki values of 1.5 µM for branched-chain amino acid-preferring activities, 2.3 µM for small neutral amino acid-preferring activities, and 40.5 µM for chymotrypsin-like activities, with an IC50 of 3.1 µM for peptidyl-glutamyl peptide hydrolyzing activity. This compound is valuable for research applications focusing on proteasomal functions and related pathways in cellular processes.

NC-002 is a cell-permeable trypsin-like proteasome inhibitor that selectively targets the proteasome while sparing lysosomal cysteine proteases. This epoxyketone derivative of Leupeptin enhances the sensitivity of myeloma cells to Bortezomib and Carfilzomib, making it a valuable tool for cancer research. NC-002's unique mechanism offers potential insights into proteasome-related pathways and therapeutic strategies in oncology.

(+)-Catechin 3-gallate is a polyphenolic compound that functions as a non-selective proteasome inhibitor. It demonstrates antitumor activity by inducing apoptosis and decreasing the levels of inflammatory cytokines. This agent is of significant interest in cancer research, particularly for breast and prostate cancers, as well as in the study of neurodegenerative diseases such as Alzheimer's.

Z-Leu-Leu-Tyr-COCHO is a potent proteasome inhibitor that specifically targets chymotrypsin-like activity, exhibiting a Ki value of 3.0 nM. This compound is effective in the modulation of protein degradation pathways, making it a valuable tool in studies related to cancer research and cellular stress responses. Its ability to inhibit proteasome activity provides insights into various biological processes and therapeutic mechanisms.

JBIR-22 is a proteasome inhibitor that specifically targets the homodimer of the proteasome assembly factor 3, disrupting its protein-protein interactions. This disruption leads to significant cytotoxic effects on human cervical cancer cell lines, demonstrating its potential as a therapeutic agent in oncology research. The stereochemical structure of JBIR-22 has been elucidated through total synthesis, supporting its further investigation in cancer studies.

SAP2-IN-1 is a potent inhibitor of secreted aspartic protease 2 (SAP2), characterized by an IC50 value of 0.92 μM. This compound serves as a virulence factor inhibitor, making it valuable for studying the role of SAP2 in pathogenesis. Due to its unique mechanism, SAP2-IN-1 can be utilized in research focused on infectious diseases and the mechanisms of microbial virulence.

INVA8001 is a highly selective and orally active chymase inhibitor, demonstrating significant potency with IC50 values of 0.02 μM for human chymase and 0.03 μM for mouse mast cell proteinase 4 (mMCP-4). This compound exhibits remarkable selectivity over related serine proteases, with IC50 values of 3.4 μM for bovine α-chymotrypsin and 32.1 μM for human cathepsin G, showcasing over 1000-fold selectivity. INVA8001 has been shown to inhibit mast cell activity in a mouse model of primary sclerosing cholangitis (PSC), leading to improved bile duct pathology and reduced bile stasis, thus highlighting its potential anti-inflammatory and anti-fibrotic applications in research.

LMP7/LMP2-IN-1 is a potent inhibitor of the immunoproteasome subunits LMP7 and LMP2, exhibiting IC50 values of 257 nM and 10 nM, respectively. This compound effectively reduces antibody production and downregulates B cells in the germinal centers of the spleen as well as plasma cells in NP-OVA-immunized mice. LMP7/LMP2-IN-1 is valuable for research into autoimmune diseases and the modulation of immune responses.

Phepropeptin B is a proteasome inhibitor that demonstrates a potent inhibitory effect with an IC50 of 11 μg/mL. This microbial secondary metabolite plays a crucial role in the regulation of protein degradation, making it a valuable tool in studies related to cancer research and cellular processes involving proteostasis. Its application extends to exploring the mechanisms of diseases where proteasome activity is dysregulated.

Cerpegin is a potent inhibitor of the 20S proteasome, which plays a critical role in the degradation of ubiquitinated proteins. This compound exhibits significant biological activities including anti-inflammatory, analgesic, and antiulcer effects, making it a valuable tool in research focused on proteasome-related pathways and therapeutic applications. Its mechanism of action allows for exploration in models of neuroprotection and various inflammatory conditions.

Phepropeptin D is a microbial secondary metabolite that functions as a proteasome inhibitor, exhibiting an IC50 of 7.8 μg/mL. This compound plays a significant role in the regulation of protein degradation pathways, making it valuable for studies related to cellular proteostasis and cancer research. Its ability to modulate proteasome activity positions Phepropeptin D as a useful tool for investigating therapeutic strategies targeting proteasome-mediated pathways.

JBJ-08-178-01 is a selective tyrosine kinase inhibitor targeting mutant forms of the human epidermal growth factor receptor 2 (HER2). It demonstrates significant antitumor activity by reducing both the kinase activity and protein levels of HER2 through the induction of proteasomal degradation. This compound holds potential for research applications in non-small-cell lung cancer, providing insights into therapeutic mechanisms against HER2-driven malignancies.

4-Nitrochalcone serves as a proteasome inhibitor, specifically targeting the proteasomal degradation pathway. It effectively inhibits the activity of NF-κB induced by TNFα, making it a valuable tool for studying inflammatory processes and signaling pathways. This compound is utilized in research focused on cancer, neurodegenerative diseases, and other conditions where proteasome activity plays a critical role.

Phepropeptin A is a microbial secondary metabolite that functions as a potent proteasome inhibitor, exhibiting an IC50 of 21 μg/mL. This compound is valuable for research applications focusing on the regulation of protein degradation pathways. Phepropeptin A can be utilized in studies aimed at understanding the role of proteasomal inhibition in cellular processes and disease models, particularly in cancer research and neurodegenerative disorders.

Phepropeptin C is a proteasome inhibitor with a reported IC50 of 12.5 μg/mL. This microbial secondary metabolite disrupts protein degradation pathways, leading to the accumulation of regulatory proteins and altered cellular responses. Its ability to modulate proteasome activity makes it a valuable tool for research into cancer biology and other diseases characterized by dysregulated protein homeostasis.

BI-1942 is a potent chymase inhibitor with an IC50 of 0.4 nM for human chymase. This chemical probe is primarily utilized in research related to ophthalmic diseases, enabling the exploration of chymase's role in ocular pathologies. Its selective inhibition provides a valuable tool for investigating the therapeutic potential in conditions where chymase is implicated.

RID-F (Ridaifen-F) is a nonpeptidic proteasome inhibitor that targets the human 20S proteasome. It demonstrates significant inhibitory activity with IC50 values of 0.64 µM for caspase-like (CT-L), 0.34 µM for trypsin-like (T-L), and 0.43 µM for post-glutamyl (PGPH) activities. RID-F is utilized in research focused on cellular degradation pathways, cancer biology, and therapeutic approaches targeting proteasome dysfunction.

Chymase-IN-2 is a potent proteasome inhibitor that selectively modulates chymase activity. It exhibits significant efficacy in addressing inflammatory responses and disorders associated with serine protease activity. This compound is valuable for research aimed at understanding protease-mediated pathways and their implications in various diseases.

Neurodegenerative Disorder-Targeting Compound 1 is a proteasome inhibitor that selectively targets calpain activity. This compound is designed to modulate cellular protein turnover, making it a valuable tool for studying the mechanisms of neurodegeneration. Its application spans various research areas, including the investigation of proteolytic pathways in neurodegenerative disorders and the exploration of therapeutic interventions aimed at enhancing neuronal survival.